STRIDES PHARMA SCIENCE LIMITED — Earnings Release 2026

Jan 30, 2026

==> picture [145 x 48] intentionally omitted <==

January 30, 2026

BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001

Scrip code: 532531 Dear Madam/ Sir,

National Stock Exchange of India Limited Exchange Plaza, Bandra-Kurla Complex Bandra (E) Mumbai - 400 051

Symbol: STAR

Sub: Press Release

Please find enclosed herewith Press Release issued by the Company titled:

“Strides Continues to Deliver Exceptional Performance With Highest Ever Quarterly EBITDA of ₹2,359m in Q3FY26”

The Board Meeting for considering the unaudited financial results for the quarter and nine months ended December 31, 2025 commenced at 10:45 hrs IST and concluded at 12:35 hrs IST.

The above information will also be available on website of the Company at www.strides.com.

This is for your information and records.

Thanks & Regards, For Strides Pharma Science Limited, Digitally signed by MANJULA MANJULA RAMAMURTHY RAMAMURTHY Date: 2026.01.30 12:37:23 +05'30'

Manjula Ramamurthy Company Secretary & Compliance Officer ICSI Membership No.: A30515

Encl. As above

Strides Pharma Science Limited CIN: L24230MH1990PLC057062 Corp. Off: Strides House, Bilekahalli, Bannerghatta Road, Bengaluru - 560 076, India Tel: +91-80-6784 0000 Fax: +91 80 6784 0700 Regd Off: ‘ Cyber One’, Unit No. 902, Plot No. 4 & 6, Sector 30A, Vashi, Navi Mumbai - 400 703, India Tel: +91-22-2789 2924/ 3199 corpcomm@strides.com; www.strides.com

Press Release January 30, 2026

==> picture [132 x 51] intentionally omitted <==

Strides Continues to Deliver Exceptional Performance With Highest Ever Quarterly EBITDA of ₹2,359m in Q3FY26

Q3FY26 Operational PAT at ₹1,282m and EPS at ₹13.9, Grew ~39% YoY Tepid Revenue Growth at 3.6%, Impacted by Low Offtake in Institutional Business and Flattish US Operations Compensated by Strong Ex-US Business, which Grew 20%YoY

Q3FY2026 Performance Highlights

• Revenue at ₹11,946m, grew 3.6% YoY

• Absolute gross margin at ₹7,317m, grew 8.6% YoY

• Gross margin improved to 61.2%, up 280bps YoY

• EBITDA grew 12.2% YoY to ₹2,359m, EBITDA margin at 19.8%, grew 160bps YoY

• Ex-US Market Revenue at $64m, reported a strong growth of 20% YoY

• Operational PAT at ₹1,282m, Grew 38.6% YoY

• Operational EPS at ₹13.9

• Reported PAT at ₹2,081m

Bangalore, India, January 30, 2026 - Strides Pharma Science Ltd (BSE: 532531, NSE: STAR) today announced its consolidated financial results for the quarter (Q3FY26) and nine months (9MFY26) ended December 31, 2025.

Financial Highlights (In ₹ m)

Particulars	Q3 FY26	Q3 FY25	YoY	Q2 FY26	QoQ	9MFY26	9MFY25	YoY
Revenue	11,946	11,537	3.6%	12,208	-2.1%	35,352	33,749	4.7%
Gross Margin	7,317	6,735	8.6%	7,056	3.7%	21,127	18,939	11.6%
Gross Margin %	61.2%	58.4%	280 bps	57.8%	340 bps	59.8%	56.1%	370 bps
EBITDA	2,359	2,103	12.2%	2,316	1.9%	6,856	5,849	17.2%
EBITDA %	19.8%	18.2%	160 bps	19.0%	80 bps	19.4%	17.3%	210 bps
Operational PAT	1,282	925	38.6%	1,403	-8.6%	3,824	2,317	65.0%
Operational EPS (₹)	13.9	10.0	38.4%	15.2	-8.6%	41.5	25.2	64.7%

Operational PAT = Reported PAT excluding exceptional items and one time income FY25 Numbers presented reflect the restated financials post the demerger of Softgel business

Badree Komandur, MD & Group CEO, commented on the performance and said, “Strides continues to deliver a strong performance in Q3FY26 with growth primarily driven by the Other Regulated Markets and Growth Markets. Our strong focus on profitability resulted in gross margin expansion of 280bps YoY, and EBITDA margin increase of 160bps YoY to 19.8%. Operational PAT and Operational EPS registered a growth of ~38% YoY. This performance demonstrates our consistent execution as we continue to invest in sustainable, longterm growth. We are also delighted to welcome Peter Hardwick as the CEO of our North America business. His leadership experience, along with strategic insights of the region, will play a key role in driving our long term growth. Our ongoing commitment to ESG continues to be recognised, with an improved S&P Global Corporate Sustainability Assessment score of 80, marking a 5 point increase over the previous year.”

About Strides

Strides, a global pharmaceutical company headquartered in Bengaluru, India, is listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR). The Company mainly operates in the

regulated markets and has an “in Africa for Africa” strategy and an institutional business to service donorfunded markets. The Company’s global manufacturing sites are located in India (Chennai, Puducherry, and two locations in Bengaluru), Italy (Milan), Kenya (Nairobi), and the United States (New York). The Company focuses on “difficult to manufacture” products sold in over 100 countries. Additional information is available at the Company’s website at www.strides.com.

For further information, please contact:

Institutional Investors Vikesh Kumar Group CFO Email:investor-relations@strides.com Saurabh Ambaselkar Investor Relations - +91 99609 31220 Email:saurabh.ambaselkar@strides.com Strides Pharma Science Limited CIN: L24230MH1990PLC057062 Corp. Office: Strides House, Bannerghatta Road, Bengaluru – 560076		Corporate Communication Pallavi Panchmatia:+91 80 6784 0193 Email: pallavi.panchmatia@strides.com Abhilash Mukherjee:+91 80 6784 0193 Email:abhilash.mukherjee@strides.com Adrita Chatterjee:+91 92842 40813 Email:adrita.chatterjee@adfactorspr.com